Skip to main content

Table 2 Risk factors for hospital mortality on entire ICU cohort with candidaemia

From: Determinants of mortality in non-neutropenic ICU patients with candidaemia

Variable Dying patients* Surviving patients* Univariate analysis** Multivariate analysis†
    Unadjusted HR (95% CI) P Adjusted HR (95% CI)†† P
Male sex 55/97 (57%) 45/76 (59%) 1.00 (0.67 to 1.49) 0.99   
Age 63.3 ± 16.7 years 51.1 ± 19.2 years 1.03 (1.01 to 1.04) <0.001 1.03 (1.01 to 1.4) <0.001
Antifungal agents prior to diagnosis 10/96 (10%) 6/76 (8%) 1.03 (0.53 to 1.98) 0.93   
Non-receipt of antifungal agents after diagnosis 20/97 (21%) 5/76 (7%) 5.17 (3.08 to 8.68) <0.001 7.90 (3.73 to 16.71) <0.001
Candida albicans 43/97 (44%) 26/76 (34%) 0.73 (0.49 to 1.10) 0.13   
Vascular access device removed or not in place 55/80 (69%) 64/79 (84%) 0.41 (0.26 to 0.67) <0.001   
TPN receipt 53/96 (55%) 26/76 (34%) 1.52 (1.02 to 2.28) 0.04   
Haemodialysis 23/97 (24%) 8/76 (11%) 1.66 (1.04 to 2.66) 0.03   
Corticosteroid receipt 33/97 (34%) 20/76 (26%) 1.36 (0.89 to 2.07) 0.17   
Non-multitrauma patient 93/97 (96%) 60/76 (79%) 3.25 (1.19 to 8.87) 0.02 6.97 (1.64 to 29.67) 0.009
Recent surgery 71/97 (73%) 47/76 (62%) 1.24 (0.79 to 1.94) 0.35   
Other healthcare related infections 73/97 (75%) 55/76 (72%) 0.85 (0.53 to 1.35) 0.49   
Ventilation at day 1 82/96 (85%) 55/76 (72%) 1.51 (0.86 to 2.67) 0.15 4.03 (1.93 to 8.41) <0.001
Sepsis at day 1 86/97 (89%) 60/76 (79%) 1.33 (0.71 to 2.49) 0.37   
Time to initiation of systemic antifungal 2.0 ± 1.3 days 2.3 ± 1.6 days 0.88 (0.75 to 1.04) 0.13   
  1. * n/N (%) or mean ± standard deviation shown; **Only significant (P < 0.05) and selected non-significant variables on univariate analysis are shown; †Only significant variables on multivariate analysis are shown; ††Adjusted for other variables in the model.
  2. CI = confidence interval; HR = hazard ratio; ICU = intensive care unit; TPN = total parenteral nutrition.